Skip to Content
Merck
  • Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

European journal of medicinal chemistry (2011-04-26)
Elisa Nuti, Francesca Casalini, Salvatore Santamaria, Pamela Gabelloni, Sara Bendinelli, Eleonora Da Pozzo, Barbara Costa, Luciana Marinelli, Valeria La Pietra, Ettore Novellino, M Margarida Bernardo, Rafael Fridman, Federico Da Settimo, Claudia Martini, Armando Rossello
ABSTRACT

Matrix metalloproteinases (MMPs) are important factors in gliomas since these enzymes facilitate invasion into the surrounding brain and participate in neovascularization. In particular, the gelatinases (MMP-2 and MMP-9), and more recently MMP-25, have been shown to be highly expressed in gliomas and have been associated with disease progression. Thus, inhibition of these MMPs may represent a promising non-cytotoxic approach to glioma treatment. We report herein the synthesis and biological evaluation of a series of 4-butylphenyl(ethynylthiophene)sulfonamido-based hydroxamates. Among the new compounds tested, a promising derivative, 5a, was identified, which exhibits nanomolar inhibition of MMP-2, MMP-9, and MMP-25, but weak inhibitory activity toward other members of the MMP family. This compound also exhibited anti-invasive activity of U87MG glioblastoma cells at nanomolar concentrations, without affecting cell viability.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine, 96%
SKU
Pack Size
Availability
Price
Quantity